Epidemiology of multiple myeloma in Taiwan, a population based study

Chao Hsiun Tang, Hung Yi Liu, Hsin An Hou, Hong Qiu, Kuan Chih Huang, Sarah Siggins, Lee Anne Rothwell, Yanfang Liu

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Although the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia. Methods: We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diagnosed confirmed MM patients during 2007–2012 were enrolled. Patients were followed up until death or end of the observation period (December 31, 2013), whichever occurred first. Results: A total of 2723 newly diagnosed MM patients were included in the cohort analysis, of whom 58.0% (1578/2723) were men. The average age of MM patients was 67.6 years. At the time of diagnosis, the mean Charlson Comorbidity Index was 1.8, 35.3% of patients had anemia, 18.0% had bone fracture, 16.4% had renal disease and 17.3% had pneumonia. The crude annual incidence of newly diagnosed MM increased from 1.74 per 100 000 population in 2007 to 2.27 per 100 000 population in 2012 (p < 0.0001), and the age-adjusted incidence from 1.41 to 1.59 per 100 000 population (p = 0.01). The use of novel treatments expanded over the study period. The crude and age-adjusted annual MM mortality rate did not change significantly over time. Case fatality decreased from 25.5% in 2007 to 19.4% in 2012 (p < 0.0001). Conclusion: The age-adjusted incidence of MM in Taiwan increased by 13% between 2007 and 2012. Despite the introduction of new treatments, MM remains largely incurable with 19.4% mortality.

Original languageEnglish
Pages (from-to)136-141
Number of pages6
JournalCancer Epidemiology
Volume55
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Multiple Myeloma
Taiwan
Epidemiology
Population
Incidence
Cohort Studies
Mortality
Health Services Research
Bone Fractures
Insurance
Comorbidity
Anemia
Pneumonia
Retrospective Studies
Observation
Databases
Kidney
Therapeutics

Keywords

  • Asia
  • Bortezomib
  • Epidemiology
  • Incidence
  • Mortality
  • Multiple myeloma
  • Prevalence

ASJC Scopus subject areas

  • Epidemiology
  • Oncology
  • Cancer Research

Cite this

Tang, C. H., Liu, H. Y., Hou, H. A., Qiu, H., Huang, K. C., Siggins, S., ... Liu, Y. (2018). Epidemiology of multiple myeloma in Taiwan, a population based study. Cancer Epidemiology, 55, 136-141. https://doi.org/10.1016/j.canep.2018.06.003

Epidemiology of multiple myeloma in Taiwan, a population based study. / Tang, Chao Hsiun; Liu, Hung Yi; Hou, Hsin An; Qiu, Hong; Huang, Kuan Chih; Siggins, Sarah; Rothwell, Lee Anne; Liu, Yanfang.

In: Cancer Epidemiology, Vol. 55, 01.08.2018, p. 136-141.

Research output: Contribution to journalArticle

Tang, CH, Liu, HY, Hou, HA, Qiu, H, Huang, KC, Siggins, S, Rothwell, LA & Liu, Y 2018, 'Epidemiology of multiple myeloma in Taiwan, a population based study', Cancer Epidemiology, vol. 55, pp. 136-141. https://doi.org/10.1016/j.canep.2018.06.003
Tang, Chao Hsiun ; Liu, Hung Yi ; Hou, Hsin An ; Qiu, Hong ; Huang, Kuan Chih ; Siggins, Sarah ; Rothwell, Lee Anne ; Liu, Yanfang. / Epidemiology of multiple myeloma in Taiwan, a population based study. In: Cancer Epidemiology. 2018 ; Vol. 55. pp. 136-141.
@article{7af55199eb5042e8afc0d4466c746d75,
title = "Epidemiology of multiple myeloma in Taiwan, a population based study",
abstract = "Background: Although the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia. Methods: We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diagnosed confirmed MM patients during 2007–2012 were enrolled. Patients were followed up until death or end of the observation period (December 31, 2013), whichever occurred first. Results: A total of 2723 newly diagnosed MM patients were included in the cohort analysis, of whom 58.0{\%} (1578/2723) were men. The average age of MM patients was 67.6 years. At the time of diagnosis, the mean Charlson Comorbidity Index was 1.8, 35.3{\%} of patients had anemia, 18.0{\%} had bone fracture, 16.4{\%} had renal disease and 17.3{\%} had pneumonia. The crude annual incidence of newly diagnosed MM increased from 1.74 per 100 000 population in 2007 to 2.27 per 100 000 population in 2012 (p < 0.0001), and the age-adjusted incidence from 1.41 to 1.59 per 100 000 population (p = 0.01). The use of novel treatments expanded over the study period. The crude and age-adjusted annual MM mortality rate did not change significantly over time. Case fatality decreased from 25.5{\%} in 2007 to 19.4{\%} in 2012 (p < 0.0001). Conclusion: The age-adjusted incidence of MM in Taiwan increased by 13{\%} between 2007 and 2012. Despite the introduction of new treatments, MM remains largely incurable with 19.4{\%} mortality.",
keywords = "Asia, Bortezomib, Epidemiology, Incidence, Mortality, Multiple myeloma, Prevalence",
author = "Tang, {Chao Hsiun} and Liu, {Hung Yi} and Hou, {Hsin An} and Hong Qiu and Huang, {Kuan Chih} and Sarah Siggins and Rothwell, {Lee Anne} and Yanfang Liu",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.canep.2018.06.003",
language = "English",
volume = "55",
pages = "136--141",
journal = "Cancer Epidemiology",
issn = "1877-7821",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Epidemiology of multiple myeloma in Taiwan, a population based study

AU - Tang, Chao Hsiun

AU - Liu, Hung Yi

AU - Hou, Hsin An

AU - Qiu, Hong

AU - Huang, Kuan Chih

AU - Siggins, Sarah

AU - Rothwell, Lee Anne

AU - Liu, Yanfang

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Background: Although the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia. Methods: We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diagnosed confirmed MM patients during 2007–2012 were enrolled. Patients were followed up until death or end of the observation period (December 31, 2013), whichever occurred first. Results: A total of 2723 newly diagnosed MM patients were included in the cohort analysis, of whom 58.0% (1578/2723) were men. The average age of MM patients was 67.6 years. At the time of diagnosis, the mean Charlson Comorbidity Index was 1.8, 35.3% of patients had anemia, 18.0% had bone fracture, 16.4% had renal disease and 17.3% had pneumonia. The crude annual incidence of newly diagnosed MM increased from 1.74 per 100 000 population in 2007 to 2.27 per 100 000 population in 2012 (p < 0.0001), and the age-adjusted incidence from 1.41 to 1.59 per 100 000 population (p = 0.01). The use of novel treatments expanded over the study period. The crude and age-adjusted annual MM mortality rate did not change significantly over time. Case fatality decreased from 25.5% in 2007 to 19.4% in 2012 (p < 0.0001). Conclusion: The age-adjusted incidence of MM in Taiwan increased by 13% between 2007 and 2012. Despite the introduction of new treatments, MM remains largely incurable with 19.4% mortality.

AB - Background: Although the incidence of multiple myeloma (MM) in Asia is lower than in Western countries, it is steadily increasing. However, limited data are available that describe the epidemiology of MM in Asia. Methods: We conducted a retrospective cohort study using the Taiwan National Healthcare Insurance Research database to estimate the disease burden and clinical characteristics of patients with MM in Taiwan. All newly diagnosed confirmed MM patients during 2007–2012 were enrolled. Patients were followed up until death or end of the observation period (December 31, 2013), whichever occurred first. Results: A total of 2723 newly diagnosed MM patients were included in the cohort analysis, of whom 58.0% (1578/2723) were men. The average age of MM patients was 67.6 years. At the time of diagnosis, the mean Charlson Comorbidity Index was 1.8, 35.3% of patients had anemia, 18.0% had bone fracture, 16.4% had renal disease and 17.3% had pneumonia. The crude annual incidence of newly diagnosed MM increased from 1.74 per 100 000 population in 2007 to 2.27 per 100 000 population in 2012 (p < 0.0001), and the age-adjusted incidence from 1.41 to 1.59 per 100 000 population (p = 0.01). The use of novel treatments expanded over the study period. The crude and age-adjusted annual MM mortality rate did not change significantly over time. Case fatality decreased from 25.5% in 2007 to 19.4% in 2012 (p < 0.0001). Conclusion: The age-adjusted incidence of MM in Taiwan increased by 13% between 2007 and 2012. Despite the introduction of new treatments, MM remains largely incurable with 19.4% mortality.

KW - Asia

KW - Bortezomib

KW - Epidemiology

KW - Incidence

KW - Mortality

KW - Multiple myeloma

KW - Prevalence

UR - http://www.scopus.com/inward/record.url?scp=85048867727&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048867727&partnerID=8YFLogxK

U2 - 10.1016/j.canep.2018.06.003

DO - 10.1016/j.canep.2018.06.003

M3 - Article

VL - 55

SP - 136

EP - 141

JO - Cancer Epidemiology

JF - Cancer Epidemiology

SN - 1877-7821

ER -